Company Overview and News

0
Ujaas Energy Limited - Investor Presentation

2018-07-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533644 UJAAS

0
Movers Shakers: Volumes of Nath Bio Genes Digjam rose the most in last 5 days

2018-07-12 moneycontrol
The market is trading on a positive note and in complete control of the bulls this Thursday afternoon with the Nifty at 11,042 and the Sensex up 345 points at 36,610.
533644 526582 UJAAS TPLPLAST RAMAVISION 523289

0
Ujaas Energy Limited - Investor Presentation

2018-07-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533644 UJAAS

0
Movers Shakers: Volumes of Artemis Global Bharti Infratel rose up to 21,000% in last 5 days

2018-07-11 moneycontrol
The market ended flat on Wednesday afternoon with the Nifty at 10,948.30 and the Sensex gaining 26 points at 36,265.
BHRYY CARBORUNIV HOVS 533096 513375 533644 532761 TCIFINANCE 532284 534816 UJAAS TCFCFINQ INFRATEL ADANIPOWER 501242

4
Over 160 stocks hit fresh 52-week low on BSE; DEN Networks, Hathway, BHEL, Andhra Bank top losers

2018-07-06 moneycontrol
The Indian benchmark indices are trading on a positive note this Friday afternoon with the Nifty adding 47 points and is trading at 10,796 mark. The Sensex is trading higher by 147 points at 35,722.
BAJAJ-AUTO 532938 CAPF 532418 532977 514034 532953 533137 VISASTEEL DEN 533644 532121 INOXWIND JBFIND VGUARD 500477 500570 BEL 500493 TATAMOTORS BHARATFORG ASHOKLEY BHQRY CONART 532721 AKLD FINOLEXIND UJAAS 501455 500940 522231 500049 GREAVESCOT 539083 DENABANK AKLS ANDHRABANK TTM

0
Ujaas Energy Limited - Reply to Clarification Sought

2018-07-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533644 UJAAS

0
Ujaas Energy Limited - Credit Rating

2018-07-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533644 UJAAS

2
Ujaas Energy Limited - Clarification

2018-07-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533644 UJAAS

2
Ujaas Energy Limited - Credit Rating

2018-06-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533644 UJAAS

2
Ujaas Energy Limited - Updates

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533644 UJAAS

2
Ujaas Energy Limited - Outcome of Board Meeting

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533644 UJAAS

2
Ujaas Energy Limited - Financial Result Updates

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533644 UJAAS

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...